Clinical trials: tuberculosis
HIV I Infection, Tuberculosis
Evaluating the Safety and Immunogenicity of MTBVAC
The purpose of this study is to evaluate the safety and immunogenicity of MTBVAC in adolescents and adults living with and without HIV in South Africa
- Trial name
- HVTN605A5421 (NCT05947890)
- Testing
- MTBVAC, BCG
- Where
- 16 sites in South Africa
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
Inflammatory Bowel Disease, Crohn Disease
The Role of IGRA in Screening and Monitoring for TB During Anti TNF Therapy in Patients With IMID
Hong Kong is a region of intermediate TB burden, and the reactivation of latent TB in IMID patients treated with anti-TNF can be a serious problem.
- Conditions
- Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Tuberculosis
- Trial name
- IGRA (NCT02135289)
- Where
- Hong Kong
- Volunteers
- 9,160 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
HIV Infections, Tuberculosis
Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults
Rifampin (RIF) is used for the treatment of tuberculosis (TB), an infectious disease that affects many people with HIV. RIF was shown to lower concentrations and decrease the effectiveness of some anti-HIV drugs, including the…
- Trial name
- NCT00096850
- Testing
- Atazanavir, Rifampin, Ritonavir
- Where
- 3 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mycobacterium Tuberculosis
A Cluster-Randomized Trial of DOTS vs DOTS Plus Active Case Finding
The purpose of the study is to see if one plan for identifying and treating tuberculosis (TB) works better than another in reducing new cases of TB.
- Trial name
- NCT00414882
- Where
- Brazil
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults
The study is a randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mtb vaccine when administered…
- Trial name
- NCT06062238
- Testing
- M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine
- Where
- 54 sites in Indonesia, Kenya and 3 more
- Volunteers
- 20,080 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Latent Tuberculosis
Ultralow Dose Computed Tomography in High-risk Drug-resistant Tuberculosis Contacts
To evaluate CT abnormalities in the lung parenchyma in close contacts at high risk for developing multidrug- or extensively drug-resistant Tb by using a follow-up ultralow dose CT scan.
- Trial name
- NCT02454738
- Testing
- Ultralow dose chest CT scan
- Where
- South Korea
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Tuberculosis
Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of single and then multiple doses of MK-7762 (TBD09) in healthy volunteers in the context of a first-in-human study.
- Trial name
- NCT05824091
- Testing
- MK-7762 (TBD09)
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Tuberculosis
Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects
This is a phase I randomized, double blind clinical trial designed to evaluate the safety, tolerability and immunogenicity of the ID93 recombinant protein antigen alone or formulated with GLA-SE or AP10-602 adjuvant in 70 healthy…
- Trial name
- NCT02508376
- Testing
- AP10-602, GLA-SE, ID93
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
Tuberculosis Vaccine in Healthy Indian Adults
An Open-labelled, Phase I Clinical Trial to Assess the Safety, Reactogenicity, Tolerability, and Immunogenicity of MTBVAC in healthy Indian adult volunteers A total of 30 subjects with Quantiferon®-TB Gold Plus assay negative and…
- Trial name
- BBV169/2023 (NCT06438978)
- Testing
- Tuberculosis Vaccine
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Tuberculosis
Influence of Filarial Infections on Tuberculosis Disease and Tuberculosis Vaccination in Cameroon
Filarial nematodes modulate the host immune response to promote regulatory and T helper type 2 immune responses, which were shown to influence concomitant infections.
- Trial name
- MAP-TB (NCT04547738)
- Testing
- TB treatment according to national guidelines
- Where
- Cameroon
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Tuberculosis
ID93/GLA-SE Vaccination + BCG Challenge
The purpose of this study is to: 1. Demonstrate the safety of a novel TB vaccine (ID93/GLA-SE) when given to both BCG-vaccinated and BCG-naïve volunteers. 2.
- Trial name
- NCT06670755
- Testing
- ID93/GLA-SE, BCG Danish
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
Non-invasive TB Triage and Patient Mapping Platform Using Breath Via Low-Cost Titanium Dioxide Nanotube Sensor
The purpose of this pilot study is to evaluate the sensitivity and specificity of a nanotube-based point-of-care breath-based tuberculosis screening test as compared to the current standards of care including sputum microscopy…
- Trial name
- NCT02681445
- Testing
- Breath Collection
- Where
- India
- Volunteers
- 810 people, healthy volunteers welcome
- Sponsor
- University of Utah
Latent Tuberculosis Infection, HIV Infections
Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection
HIV induced altered representation and function of regulatory T cell subsets (NKT and Treg cells) impair the protective T cell response against M.tuberculosis and disrupts LTBI, thus facilitates faster progression and development…
- Conditions
- Latent Tuberculosis Infection, HIV Infections, Tuberculosis
- Trial name
- HIV-TB (NCT00692809)
- Where
- India
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Ministry of Science and Technology, India
Healthy Volunteers
A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women
The purpose of this trial is to assess the potential for cytochrome P450 (CYP)-mediated drug-drug interactions (DDIs) with OPC-167832.
- Trial name
- NCT07542847
- Testing
- OPC-167832, Itraconazole, Carbamazepine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Rifampicin-Resistant Pulmonary Tuberculosis Patients
Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults
The goal of this clinical trial is to learn how Sudapyridine (WX-081) tablets interact with other drugs and how food intake affects its pharmacokinetics in healthy Chinese adults.
- Trial name
- WX081-DDI (NCT06701136)
- Testing
- Sudapyridine, Itraconazole, Rifampin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
Tuberculosis
A Study to Evaluate Safety and Immunogenicity of AERAS-402
This Phase I study will be conducted as a randomized, double-blind, placebo-controlled study in healthy adult subjects who are HIV-negative, BCG-vaccinated, and have no evidence of tuberculosis infection.
- Trial name
- NCT01378312
- Testing
- AERAS 402
- Where
- India
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Aeras
Tuberculosis, Pulmonary
Cost-effectiveness of Two Forms of DOTS in a Demonstration Area of the DOTS Strategy in Colombia
Tuberculosis ( TB ) remains a major global public health problems and actions to ensure the diagnosis and complete treatment of all cases is the priority for the control of this disease.
- Trial name
- DOTS (NCT01945905)
- Testing
- Intramural, Extramural
- Where
- Colombia
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Fundación FES
Multidrug-resistant Tuberculosis (MDR-TB)
Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge in Central Africa. Understanding the molecular epidemiology and genotypic characteristics of MDR-TB strains is crucial for effective control measures.
- Trial name
- MESTCAR (NCT07017803)
- Where
- 8 sites in Gabon
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
TB - Tuberculosis, Silicosis
KAP TB in Senior Management Officials of Companies With Increased Silica Exposure
The study was designed as a descriptive cross-sectional survey conducted between February and October 2022. Senior management officials were targeted because of their role in workplace policy and oversight.
- Conditions
- TB - Tuberculosis, Silicosis, Occupational Exposure, Occupational Health
- Trial name
- KAP TB (NCT07749872)
- Where
- Zambia
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Tuberculosis
BCG Vaccination Delivered Intradermally, Orally and by Combined Routes
This study will assess the safety of a Bacillus Calmette-Guérin (BCG) vaccine against tuberculosis (TB) and will evaluate if giving the vaccine by mouth, injection, or by both methods produces greater results.
- Trial name
- NCT00396370
- Testing
- BCG strain Connaught, BCG strain Danish
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)